B-cell defects in common variable immunodefciency: BCR signaling, protein clustering and hardwired gene mutations

Critical Reviews in Immunology

Volumn 31, Issue 2, 2011, Pages 85-98

  van de Ven, Annick A J M ^a   Compeer, Ewoud B ^a   van Montfrans, Joris M ^a   Boes, Marianne ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Assembly; B cell receptor; Oligomerization; Primary immune defciency; Signal transduction

Indexed keywords

ANTIGEN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LIPOPOLYSACCHARIDE BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; COMMON VARIABLE IMMUNODEFICIENCY; EPIGENETICS; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; MEDICAL RESEARCH; MEMORY CELL; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA;

B-LYMPHOCYTES; COMMON VARIABLE IMMUNODEFICIENCY; EPIGENESIS, GENETIC; HUMANS; IMMUNOLOGIC MEMORY; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 79955654098     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Wood PM. Primary antibody defciency syndromes. Curr. Opin.Hematol. 17(4), 356-361. 2010.
2. Primary immunodefciency diseases. Report of an IUIS Scientifc Committee. International Union of Immunological Societies. Clin. Exp. Immunol. 118 Suppl 1, 1-28. 1999.
3. European Society for Immunodefciencies. Diagnostic criteria for PID: Common variable immunodefciency diagnostic criteria; 2005. [Cited 2009; March 5.] Available from. http://www.esid.org/workingparty.php?party=3&sub=2&id=73#Q3. 2009.
4. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodefciency: a new look at an old disease. Lancet 372(9637), 489-502. 2008.
5. Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans.Assoc.Am.Physicians 66, 200-202. 1953.
6. Magilavy DB, Cassidy JT, Tubergen DG, Petty RE, Chrisholm R, McCall K. Intravenous gamma globulin in the management of patients with hypogammaglobuline-mia. J.Allergy Clin.Immunol. 61(6), 378-383. 1978.
7. Caballero FM, Brown WR, Kohler PF, Hayward AR. B cell numbers and responses in patients with common variable immunodefciency and nodular lymphoid hyperplasia of the bowel. J.Clin.Lab Immunol. 13(2), 59-63. 1984.
8. Wright JJ, Wagner DK, Blaese RM, Hagengruber C, Wald-mann TA, Fleisher TA. Characterization of common variable immunodefciency: identifcation of a subset of patients with distinctive immunophenotypic and clinical features. Blood 76(10), 2046-2051, 15.11.1990.
9. Piqueras B, Lavenu-Bombled C, Galicier L, Bergeron-van der CF, Mouthon L, Chevret S, Debre P, Schmitt C, Ok-senhendler E. Common variable immunodefciency patient classifcation based on impaired B cell memory differentiation correlates with clinical aspects. J.Clin.Immunol. 23(5), 385-400. 2003.
10. Warnatz K, Denz A, Drager R, Braun M, Groth C, Wolff-Vorbeck G, Eibel H, Schlesier M, Peter HH. Severe de-fciency of switched memory B cells (CD27(+)IgM(-) IgD(-)) in subgroups of patients with common variable immunodefciency: a new approach to classify a heterogeneous disease. Blood 99(5), 1544-1551. 2002.
11. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlk-ova M, Hernandez M, Detkova D, Bos PR, Poerksen G, von BH, Baumann U, Goldacker S, Gutenberger S, Schlesier M, Bergeron-van der CF, Le GM, Debre P, Jacobs R, Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K. The EU-ROclass trial: defning subgroups in common variable im-munodefciency. Blood. 111(1), 77-85. 1-1-2008.
12. Yong PL, Orange JS, Sullivan KE. Pediatric common variable immunodefciency: Immunologic and phenotypic associations with switched memory B cells. Pediatr.Allergy Immunol. 2010.
13. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodefciency and IgA defciency. Nat.Genet. 37(8), 829-834. 2005.
14. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schaffer AA, Hammarstrom L, Grimbacher B. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodefciency in humans. Nat.Genet. 37(8), 820-828. 2005.
15. van Zelm MC, Reisli I, van der BM, Castano D, van No-esel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, Franco JL. An antibody-defciency syndrome due to mutations in the CD19 gene. N.Engl.J.Med. 354(18), 1901-1912. 4-5-2006.
16. Grimbacher B, Hutloff A, Schlesier M, Glocker E, War-natz K, Drager R, Eibel H, Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH. Homozygous loss of ICOS is associated with adult-onset common variable immunodef-ciency. Nat.Immunol. 4(3), 261-268. 2003.
17. Paccani SR, Boncristiano M, Patrussi L, Ulivieri C, Wack A, Valensin S, Hirst TR, Amedei A, Del PG, Telford JL, D'Elios MM, Baldari CT. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodefciency characterized by T-cell defects. Blood 106(2), 626-634. 2005.
18. Fevang B, Yndestad A, Sandberg WJ, Holm AM, Muller F, Aukrust P, Froland SS. Low numbers of regulatory T cells in common variable immunodefciency: association with chronic infammation in vivo. Clin.Exp.Immunol. 147(3), 521-525. 2007.
19. Vlkova M, Fronkova E, Kanderova V, Janda A, Ruzickova S, Litzman J, Sediva A, Kalina T. Characterization of Lymphocyte Subsets in Patients with Common Variable Immu-nodefciency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression. J.Immunol. 1-11-2010.
20. Rakhmanov M, Keller B, Gutenberger S, Foerster C, Hoe-nig M, Driessen G, van der BM, van Dongen JJ, Wiech E, Visentini M, Quinti I, Prasse A, Voelxen N, Salzer U, Goldacker S, Fisch P, Eibel H, Schwarz K, Peter HH, War-natz K. Circulating CD21low B cells in common variable immunodefciency resemble tissue homing, innate-like B cells. Proc.Natl.Acad.Sci.U.S.A 106(32), 13451-13456. 2009.
21. Foerster C, Voelxen N, Rakhmanov M, Keller B, Guten-berger S, Goldacker S, Thiel J, Feske S, Peter HH, War-natz K. B Cell Receptor-Mediated Calcium Signaling Is Impaired in B Lymphocytes of Type Ia Patients with Common Variable Immunodefciency. J.Immunol. 2010.
22. Yu JE, Knight AK, Radigan L, Marron TU, Zhang L, Sanchez-Ramon S, Cunningham-Rundles C. Toll-like receptor 7 and 9 defects in common variable immunodefciency. J.Allergy Clin.Immunol. 124(2), 349-56, 356. 2009.
23. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104(4), 487-501. 2001.
24. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278(5335), 138-141. 3-10-1997.
25. Reyes-Moreno C, Girouard J, Lapointe R, Darveau A, Mourad W. CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes. J.Biol. Chem. 279(9), 7799-7806. 27-2-2004.
26. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ. Fas preas-sociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288(5475), 2354-2357. 30-6-2000.
27. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenar-do MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288(5475), 2351-2354. 30-6-2000.
28. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF. A role for BLyS in the activation of innate immune cells. Blood 108(8), 2687-2694. 2006.
29. Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J.Immunol. 180(11), 7394-7403. 2008.
30. Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherp-fennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodefciency (CVID). J.Clin.Invest 117(6), 1550-1557. 2007.
31. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J.Exp.Med. 188(6), 1185-1190. 1998.
32. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, cha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189(11), 1747-1756. 1999.
33. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Gal-perina O, Giri J, Roschke V, Nardelli B, Carrell J, Sos-novtseva S, Greenfeld W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425), 260-263. 1999.
34. Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J.Leukoc.Biol. 65(5), 680-683. 1999.
35. Call ME, Wucherpfennig KW. Common themes in the assembly and architecture of activating immune receptors. Nat.Rev.Immunol. 7(11), 841-850. 2007.
36. Lee JJ, Rauter I, Garibyan L, Ozcan E, Sannikova T, Dillon SR, Cruz AC, Siegel RM, Bram R, Jabara H, Geha RS. The murine equivalent of the A181E TACI mutation associated with CVID severely impairs B cell function. Blood. 2009.
37. Castigli E, Wilson S, Garibyan L, Rachid R, Bonilla F, Schneider L, Morra M, Curran J, Geha R. Reexamining the role of TACI coding variants in common variable im-munodefciency and selective IgA defciency. Nat.Genet. 39(4), 430-431. 2007.
38. Pan-Hammarstrom Q, Salzer U, Du L, Bjorkander J, Cun-ningham-Rundles C, Nelson DL, Bacchelli C, Gaspar HB, Offer S, Behrens TW, Grimbacher B, Hammarstrom L. Re-examining the role of TACI coding variants in common variable immunodefciency and selective IgA defciency. Nat.Genet. 39(4), 429-430. 2007.
39. Salzer U, Bacchelli C, Buckridge S, Pan-Hammarstrom Q, Jennings S, Lougaris V, Bergbreiter A, Hagena T, Birme-lin J, Plebani A, Webster AD, Peter HH, Suez D, Chapel H, Lean-Tooke A, Spickett GP, nover-Sombke S, Ochs HD, Urschel S, Belohradsky BH, Ugrinovic S, Kumara-ratne DS, Lawrence TC, Holm AM, Franco JL, Schulze I, Schneider P, Gertz EM, Schaffer AA, Hammarstrom L, Thrasher AJ, Gaspar HB, Grimbacher B. Relevance of bi-allelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRS-F13B variants in antibody defciency syndromes. Blood. 2008.
40. Zhang L, Radigan L, Salzer U, Behrens TW, Grimbacher B, Diaz G, Bussel J, Cunningham-Rundles C. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodefcien-cy: clinical and immunologic outcomes in heterozygotes. J.Allergy Clin.Immunol. 120(5), 1178-1185. 2007.
41. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781), 995-999. 2000.
42. Laabi Y, Gras MP, Carbonnel F, Brouet JC, Berger R, Lar-sen CJ, Tsapis A. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 11(11), 3897-3904. 1992.
43. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J.Immunol. 179(11), 7276-7286. 2007.
44. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J.Immunol. 173(2), 807-817. 2004.
45. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Bohm J, Kienzler AK, Pan-Hammarstrom Q, Hammar-strom L, Rakhmanov M, Schlesier M, Grimbacher B, Peter HH, Eibel H. B-cell activating factor receptor defciency is associated with an adult-onset antibody defciency syndrome in humans. Proc.Natl.Acad.Sci.U.S.A 106(33), 13945-13950. 2009.
46. Salzer U, Neumann C, Thiel J, Woellner C, Pan-Hammar-strom Q, Lougaris V, Hagena T, Jung J, Birmelin J, Du L, Metin A, Webster DA, Plebani A, Moschese V, Hammar-strom L, Schaffer AA, Grimbacher B. Screening of functional and positional candidate genes in families with common variable immunodefciency. BMC.Immunol. 9, 3. 2008.
47. Batista FD, Treanor B, Harwood NE. Visualizing a role for the actin cytoskeleton in the regulation of B-cell activation. Immunol.Rev. 237(1), 191-204. 2010.
48. Yang J, Reth M. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature 467(7314), 465-469. 2010.
49. Reth M. Antigen receptor tail clue. Nature 338(6214), 383-384. 1989.
50. Papavasiliou F, Misulovin Z, Suh H, Nussenzweig MC. The role of Ig beta in precursor B cell transition and allelic exclusion. Science 268(5209), 408-411. 1995.
51. Torres RM, Flaswinkel H, Reth M, Rajewsky K. Aberrant B cell development and immune response in mice with a compromised BCR complex. Science 272(5269), 1804-1808. 1996.
52. Takata M, Kurosaki T. A role for Bruton's tyrosine ki-nase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J.Exp.Med. 184(1), 31-40. 1996.
53. Takata M, Sabe H, Hata A, Inazu T, Homma Y, Nukada T, Yamamura H, Kurosaki T. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J. 13(6), 1341-1349. 1994.
54. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Paw-son T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378(6554), 303-306.1995.
55. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VL. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378(6554), 298-302.1995.
56. Takata M, Homma Y, Kurosaki T. Requirement of phos-pholipase C-gamma 2 activation in surface immunoglobu-lin M-induced B cell apoptosis. J.Exp.Med. 182(4), 907-914. 1995.
57. Putney JW. Capacitative calcium entry: from concept to molecules. Immunol.Rev. 231(1), 10-22. 2009.
58. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256(5053), 105-107. 1992.
59. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271(5247), 348-350. 1996.
60. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, Ferster A, Kuo CC, Levy S, van Dongen JJ, van der BM. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody defciency. J.Clin.In-vest 120(4), 1265-1274. 2010.
61. Thiel J, Kimmig L, Salzer U, Voelxen N, Eibel H, Peter HH, Grimbacher B, rump J., Schlesier M. The Clinical and Immunological Phenotype of Human CD21 Defciency. Proceedings of the 9th Annual Meeting of the Federation of Clinical Immunology Societies; 2009 June 11-14; San Francisco, CA, U.S.A. Amsterdam: Elsevier; 2011.
62. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA. CD20 defciency in humans results in impaired T cell-independent antibody responses. J.Clin.Invest 120(1), 214-222. 2010.
63. Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J.Immunol. 169(6), 2886-2891. 2002.
64. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oli-gomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J.Biol.Chem. 283(27), 18545-18552. 2008.
65. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, Glennie MJ, Cragg MS. Induction of cy-tosolic calcium fux by CD20 is dependent upon B Cell antigen receptor signaling. J.Biol.Chem. 283(25), 16971-16984. 2008.
66. Bruton OC. Agammaglobulinemia. Pediatrics 9(6), 722-728. 1952.
67. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S,. Defcient expression of a B cell cytoplasmic tyrosine ki-nase in human X-linked agammaglobulinemia. Cell 72(2), 279-290. 1993.
68. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bo-brow M,. The gene involved in X-linked agammaglobu-linaemia is a member of the src family of protein-tyrosine kinases. Nature 361(6409), 226-233. 1993.
69. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, Kitchingman GR, Campana D, Rohrer J, Conley ME. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N.Engl.J.Med. 335(20), 1486-1493.1996.
70. Minegishi Y, Rohrer J, Coustan-Smith E, Lederman HM, Pappu R, Campana D, Chan AC, Conley ME. An essential role for BLNK in human B cell development. Science 286(5446), 1954-1957. 1999.
71. Minegishi Y, Coustan-Smith E, Rapalus L, Ersoy F, Campana D, Conley ME. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J.Clin.Invest 104(8), 1115-1121. 1999.
72. Wang Y, Kanegane H, Sanal O, Tezcan I, Ersoy F, Futatani T, Miyawaki T. Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-defcient agammaglobuline-mia. Am.J.Med.Genet. 108(4), 333-336. 2002.
73. Dobbs AK, Yang T, Farmer D, Kager L, Parolini O, Con-ley ME. Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodefciency and a leaky defect in B cell development. J.Immunol. 179(4), 2055-2059. 2007.
74. Ferrari S, Lougaris V, Caraff S, Zuntini R, Yang J, Sore-sina A, Meini A, Cazzola G, Rossi C, Reth M, Plebani A. Mutations of the Igbeta gene cause agammaglobulinemia in man. J.Exp.Med. 204(9), 2047-2051. 2007.
75. Schwartz R, Porat YB, Handzel Z, Sthoeger Z, Garty BZ, Confno-Cohen R, Levy J, Zan-Bar I. Identifcation of a subset of common variable immunodefciency patients with impaired B-cell protein tyrosine phosphorylation. Clin.Diagn.Lab Immunol. 6(6), 856-860. 1999.
76. Groth C, Drager R, Warnatz K, Wolff-Vorbeck G, Schmidt S, Eibel H, Schlesier M, Peter HH. Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodefciency (CVID). Clin. Exp.Immunol. 129(1), 133-139. 2002.
77. Denz A, Eibel H, Illges H, Kienzle G, Schlesier M, Peter HH. Impaired up-regulation of CD86 in B cells of "type A" common variable immunodefciency patients. Eur.J.Immunol. 30(4), 1069-1077. 2000.
78. Bryant A, Calver NC, Toubi E, Webster AD, Farrant J. Classifcation of patients with common variable immuno-defciency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin.Immunol.Immunop-athol. 56(2), 239-248. 1990.
79. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat.Im-munol. 11(5), 373-384. 2010.
80. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278(5343), 1612-1615.1997.
81. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 7(6), 837-847. 1997.
82. Akira S, Takeda K. Toll-like receptor signalling. Nat.Rev. Immunol. 4(7), 499-511. 2004.
83. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defned by cooperation between toll-like receptors. Proc.Natl.Acad.Sci.U.S.A 97(25), 13766-13771. 2000.
84. Bernasconi NL, Onai N, Lanzavecchia A. A role for Tolllike receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101(11), 4500-4504. 2003.
85. Bekeredjian-Ding I, Jego G. Toll-like receptors--sentries in the B-cell response. Immunology 128(3), 311-323. 2009.
86. Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune defciency. J.Immunol. 176(3), 1978-1987. 2006.
87. Escobar D, Pons J, Clemente A, Iglesias J, Regueiro V, Bengoechea JA, Matamoros N, Ferrer JM. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus infuenzae extracts in common variable immunodefciency patients. Cell Immunol. 262(2), 105-111. 2010.
88. Tanir S, Karkucak M, Yakut T, Kilic SS. Toll-like receptor-9 gene polymorphism in common variable immunodefciency. J.Investig.Allergol.Clin.Immunol. 20(3), 267-268. 2010.
89. Conley ME, Rohrer J, Rapalus L, Boylin EC, Minegishi Y. Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol.Rev. 178, 75-90. 2000.
90. Wang HY, Gopalan V, Aksentijevich I, Yeager M, Ma CA, Mohamoud YA, Quinones M, Matthews C, Boland J, Nie-mela JE, Torgerson TR, Giliani S, Uzel G, Orange JS, Shapiro R, Notarangelo L, Ochs HD, Fleisher T, Kastner D, Chanock SJ, Jain A. A custom 148 gene-based resequenc-ing chip and the SNP explorer software: new tools to study antibody defciency. Hum.Mutat. 2010.
91. Infantino S, Benz B, Waldmann T, Jung M, Schneider R, Reth M. Arginine methylation of the B cell antigen receptor promotes differentiation. J.Exp.Med. 207(4), 711-719. 2010.
92. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416(6881), 603-607. 2002.
93. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J.Exp.Med. 202(9), 1171-1177. 2005.
94. Katsenelson N, Kanswal S, Puig M, Mostowski H, Ver-thelyi D, Akkoyunlu M. Synthetic CpG oligodeoxynucle-otides augment. Eur.J.Immunol. 37(7), 1785-1795. 2007.
95. Ng LG, Ng CH, Woehl B, Sutherland AP, Huo J, Xu S, Mackay F, Lam KP. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur.J.Immunol. 36(7), 1837-1846. 2006.
96. Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, Cancro MP, Khan WN. TLR stimulation modi-fes BLyS receptor expression in follicular and marginal zone B cells. J.Immunol. 178(12), 7531-7539. 2007.
97. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB, Chiu A, Puel A, Reichenbach J, Marodi L, Doffnger R, Vasconcelos J, Issekutz A, Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C, Cunningham-Rundles C, Casanova JL, Cerutti A. The transmembrane activator TACI triggers immuno-globulin class switching by activating B cells through the adaptor MyD88. Nat.Immunol. 2010.
98. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J.Pediatr. 125(6 Pt 1), 876-885. 1994.
99. Dupre L, Aiuti A, Trifari S, Martino S, Saracco P, Bordi-gnon C, Roncarolo MG. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity. 17(2), 157-166. 2002.
100. Badour K, Zhang J, Shi F, McGavin MK, Rampersad V, Hardy LA, Field D, Siminovitch KA. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immu-nological synapse. Immunity. 18(1), 141-154. 2003.
101. Snapper SB, Rosen FS, Mizoguchi E, Cohen P, Khan W, Liu CH, Hagemann TL, Kwan SP, Ferrini R, Davidson L, Bhan AK, Alt FW. Wiskott-Aldrich syndrome protein-de-fcient mice reveal a role for WASP in T but not B cell activation. Immunity. 9(1), 81-91. 1998.
102. Westerberg L, Greicius G, Snapper SB, Aspenstrom P, Severinson E. Cdc42, Rac1, and the Wiskott-Aldrich syndrome protein are involved in the cytoskeletal regulation of B lymphocytes. Blood 98(4), 1086-1094. 2001.
103. Westerberg L, Larsson M, Hardy SJ, Fernandez C, Thrasher AJ, Severinson E. Wiskott-Aldrich syndrome protein defciency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood 105(3), 1144-1152. 2005.
104. Ruusala A, Aspenstrom P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett. 572(1-3), 159-166. 2004.
105. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woell-ner C, Lopez-Herrera G, Chen A, Kim HS, Lloret MG, Schulze I, Ehl S, Thiel J, Pfeifer D, Veelken H, Niehues T, Siepermann K, Weinspach S, Reisli I, Keles S, Genel F, Kutukculer N, Camcioglu Y, Somer A, Karakoc-Aydiner E, Barlan I, Gennery A, Metin A, Degerliyurt A, Pietro-grande MC, Yeganeh M, Baz Z, Al-Tamemi S, Klein C, Puck JM, Holland SM, McCabe ER, Grimbacher B, Cha-tila TA. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-re-cessive form of hyper-IgE syndrome. J.Allergy Clin.Im-munol. 124(6) 1289-1302. 2009.
106. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, Matthews HF, Davis J, Turner ML, Uzel G, Holland SM, Su HC. Combined immunodefciency associated with DOCK8 mutations. N.Engl.J.Med. 361(1) 2046-2055.2009.
107. Randall KL, Lambe T, Johnson AL, Treanor B, Kuchar-ska E, Domaschenz H, Whittle B, Tze LE, Enders A, Crockford TL, Bouriez-Jones T, Alston D, Cyster JG, Lenardo MJ, Mackay F, Deenick EK, Tangye SG, Chan TD, Camidge T, Brink R, Vinuesa CG, Batista FD, Cornall RJ, Goodnow CC. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat.Immunol. 10(2) 1283-1291. 2009.
108. Kanegane H, Agematsu K, Futatani T, Sira MM, Suga K, Sekiguchi T, van Zelm MC, Miyawaki T. Novel mutations in a Japanese patient with CD19 defciency. Genes Immun. 8(8), 663-670. 2007